SHANGHAI JUNSHI BIOSCIENCES CO., LTD. Financials Shanghai Junshi Biosciences Co., Ltd. Deutsche Boerse AG
Equities
8SJ
CNE100003FF7
Pharmaceuticals
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.32 EUR | -6.38% |
|
-2.94% | -49.23% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 18,711 | 64,649 | 56,686 | 57,119 | 35,947 | 23,878 | - | - |
| Enterprise Value (EV) 1 | 18,402 | 62,115 | 53,714 | 52,363 | 33,930 | 20,839 | 21,502 | 21,923 |
| P/E ratio | -24.9 x | -23.4 x | -59.1 x | - | - | -6.83 x | -9.21 x | -11.3 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 24.1 x | 40.5 x | 14.1 x | 39.3 x | 23.9 x | 11.2 x | 7.47 x | 5.77 x |
| EV / Revenue | 23.7 x | 38.9 x | 13.3 x | 36 x | 22.6 x | 9.79 x | 6.72 x | 5.3 x |
| EV / EBITDA | -23.5 x | -41.7 x | -127 x | -21.7 x | -15.7 x | -15.3 x | -21.3 x | -24.9 x |
| EV / FCF | -9.3 x | -30.5 x | -38 x | -24.1 x | -12 x | -10.3 x | -25.3 x | -15.7 x |
| FCF Yield | -10.8% | -3.28% | -2.63% | -4.14% | -8.35% | -9.7% | -3.96% | -6.36% |
| Price to Book | 6.26 x | 7.14 x | 5.17 x | - | - | 1.5 x | 1.65 x | 1.57 x |
| Nbr of stocks (in thousands) | 784,147 | 872,496 | 910,757 | 982,872 | 985,011 | 984,908 | - | - |
| Reference price 2 | 23.86 | 47.81 | 47.26 | 42.83 | 17.67 | 10.82 | 10.82 | 10.82 |
| Announcement Date | 20-03-02 | 21-02-26 | 22-02-25 | 23-02-27 | 24-02-23 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 775.1 | 1,595 | 4,025 | 1,453 | 1,503 | 2,129 | 3,198 | 4,135 |
| EBITDA 1 | -783.5 | -1,490 | -422 | -2,417 | -2,168 | -1,360 | -1,008 | -880 |
| EBIT 1 | -747.3 | -1,636 | -558.3 | -2,666 | -2,457 | -1,581 | -868.7 | -16.98 |
| Operating Margin | -96.41% | -102.59% | -13.87% | -183.41% | -163.55% | -74.27% | -27.16% | -0.41% |
| Earnings before Tax (EBT) 1 | -763.1 | -1,672 | -595 | -2,677 | -2,492 | -1,538 | -767.7 | -43.62 |
| Net income 1 | -747.4 | -1,669 | -720.9 | -2,388 | -2,283 | -1,433 | -717.5 | -85.17 |
| Net margin | -96.43% | -104.62% | -17.91% | -164.3% | -151.97% | -67.29% | -22.44% | -2.06% |
| EPS 2 | -0.9600 | -2.040 | -0.8000 | - | - | -1.583 | -1.175 | -0.9566 |
| Free Cash Flow 1 | -1,979 | -2,037 | -1,414 | -2,170 | -2,833 | -2,021 | -850.5 | -399 |
| FCF margin | -255.28% | -127.71% | -35.14% | -149.31% | -188.58% | -94.92% | -26.6% | -9.65% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 20-03-02 | 21-02-26 | 22-02-25 | 23-02-27 | 24-02-23 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: |
|---|
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 309 | 2,534 | 2,972 | 4,756 | 2,017 | 3,039 | 2,377 | 1,956 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -1,979 | -2,037 | -1,414 | -2,170 | -2,833 | -2,014 | -851 | -399 |
| ROE (net income / shareholders' equity) | -23.6% | -37.7% | -10.4% | -32.7% | -27.3% | -23.1% | -11.5% | -0.15% |
| ROA (Net income/ Total Assets) | -17.1% | -26.8% | -9.24% | - | -18.8% | -14.7% | -6.78% | -0.61% |
| Assets 1 | 4,360 | 6,228 | 7,802 | - | 12,138 | 9,766 | 10,589 | 13,863 |
| Book Value Per Share 2 | 3.810 | 6.690 | 9.150 | - | - | 7.200 | 6.550 | 6.890 |
| Cash Flow per Share 2 | -0.9100 | -1.780 | -0.7200 | - | - | -1.220 | -0.5700 | - |
| Capex 1 | 792 | 580 | 772 | 394 | 828 | 610 | 490 | 373 |
| Capex / Sales | 102.13% | 36.4% | 19.19% | 27.1% | 55.14% | 28.63% | 15.31% | 9.02% |
| Announcement Date | 20-03-02 | 21-02-26 | 22-02-25 | 23-02-27 | 24-02-23 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
10.82
CNY
Average target price
22.86
CNY
Spread / Average Target
+111.32%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -1.85% | 89.87B | |
| -1.05% | 37.57B | |
| -11.78% | 32.75B | |
| +61.85% | 26.47B | |
| -21.13% | 14.25B | |
| -6.50% | 12.99B | |
| -11.42% | 11.93B | |
| -47.67% | 10.84B | |
| +5.99% | 9.11B |
- Stock Market
- Equities
- 1877 Stock
- 8SJ Stock
- Financials Shanghai Junshi Biosciences Co., Ltd.
